blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2678012

EP2678012 - C-GLUCOSIDIC ELLAGITANNIN COMPOUNDS FOR USE FOR ALTERING THE SUPRAMOLECULAR ARRANGEMENT OF ACTIN AND FOR THE TREATMENT OF OSTEOPOROSIS, CANCER, BACTERIAL INFECTION AND VIRAL INFECTION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  19.05.2017
Database last updated on 24.04.2024
FormerExamination is in progress
Status updated on  13.02.2017
Most recent event   Tooltip19.05.2017Application deemed to be withdrawnpublished on 21.06.2017  [2017/25]
Applicant(s)For all designated states
Institut National de la Santé et de la Recherche Médicale
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Centre National de la Recherche Scientifique (C.N.R.S.)
3, rue Michel-Ange
75016 Paris / FR
[N/P]
Former [2014/01]For all designated states
Institut National de la Santé et de la Recherche Médicale
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Centre National de la Recherche Scientifique CNRS
3, rue Michel Ange
75016 Paris / FR
Inventor(s)01 / QUIDEAU, Stéphane
Université Bordeaux 1 - Institut des Sciences
Moléculaires (CNRS-UMR 5255)
2 rue Robert Escarpit
F-33607 Pessac Cedex / FR
02 / GENOT, Elisabeth
INSERM U1053 et Institut Européen de Chimie et
Biologie
2 rue Robert Escarpit
F-33607 Pessac Cedex / FR
03 / SALTEL, Frédéric
INSERM U1053 et Institut Européen de Chimie et
Biologie
2 rue Robert Escarpit
F-33607 Pessac Cedex / FR
04 / DOUAT-CASASSUS, Céline
Université Bordeaux 1 - Institut des Sciences
Moléculaires (CNRS-UMR 5255)
2 rue Robert Escarpit
F-33607 Pessac Cedex / FR
05 / DELANNOY LOPEZ, Daniela Mélanie
Université Bordeaux 1 - Institut des Sciences
Moléculaires (CNRS-UMR 5255)
2 rue Robert Escarpit
F-33607 Pessac Cedex / FR
 [2014/01]
Representative(s)Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
[N/P]
Former [2014/01]Blot, Philippe Robert Emile
Cabinet Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Application number, filing date12704839.522.02.2012
WO2012EP53017
Priority number, dateEP2011030518622.02.2011         Original published format: EP 11305186
[2014/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012113835
Date:30.08.2012
Language:EN
[2012/35]
Type: A1 Application with search report 
No.:EP2678012
Date:01.01.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 30.08.2012 takes the place of the publication of the European patent application.
[2014/01]
Search report(s)International search report - published on:EP30.08.2012
ClassificationIPC:A61K31/357, A61P35/00, A61P19/10
[2014/01]
CPC:
A61K31/357 (EP,US); A61K31/365 (US); A61P19/10 (EP);
A61P35/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/01]
TitleGerman:C-GLUCOSIDELLAGITANNIN-VERBINDUNGEN ZUR VERWENDUNG ZUR VERÄNDERUNG DER SUPRAMOLEKULAREN ANORDNUNG VON AKTIN UND ZUR BEHANDLUNG VON OSTEOPOROSE, KREBS, BAKTERIENINFEKTIONEN UND VIRUSINFEKTIONEN[2014/01]
English:C-GLUCOSIDIC ELLAGITANNIN COMPOUNDS FOR USE FOR ALTERING THE SUPRAMOLECULAR ARRANGEMENT OF ACTIN AND FOR THE TREATMENT OF OSTEOPOROSIS, CANCER, BACTERIAL INFECTION AND VIRAL INFECTION[2014/01]
French:COMPOSÉS D'ELLAGITANIN C-GLUCOSIDIQUE DESTINÉS À ÊTRE UTILISÉS POUR MODIFIER L'ARRANGEMENT SUPRAMOLÉCULAIRE DE L'ACTINE ET POUR LE TRAITEMENT DE L'OSTÉOPOROSE, DU CANCER, D'UNE INFECTION BACTÉRIENNE ET UNE D'INFECTION VIRALE[2014/01]
Entry into regional phase14.08.2013National basic fee paid 
14.08.2013Designation fee(s) paid 
14.08.2013Examination fee paid 
Examination procedure14.08.2013Amendment by applicant (claims and/or description)
14.08.2013Examination requested  [2014/01]
08.09.2016Despatch of a communication from the examining division (Time limit: M04)
19.01.2017Application deemed to be withdrawn, date of legal effect  [2017/25]
14.02.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2017/25]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.09.2016
Fees paidRenewal fee
24.02.2014Renewal fee patent year 03
24.02.2015Renewal fee patent year 04
25.02.2016Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
28.02.201706   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2007127263  (UNIV CALIFORNIA [US], et al) [X] 1-13 * paragraphs [0006] , [00 7] , [0 15] , [0 31] - [0036] - [0 67] - [0079] *;
 [X]WO2009114810  (FLORIDA INTERNAT UINVERSITY BO [US], et al) [X] 1-13* paragraphs [0015] , [0 19] - [0026]; claim - *;
 [X]US2011039796  (LIU ZHIJUN [US], et al) [X] 1-13 * paragraphs [0001] - [0006] - [0 18] *;
 [X]  - HO H H ET AL, "Anti-metastasis effects of gallic acid on gastric cancer cells involves inhibition of NF-kappaB activity and downregulation of PI3K/AKT/small GTPase signals", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 48, no. 8-9, ISSN 0278-6915, (20100801), pages 2508 - 2516, (20100618), XP027166468 [X] 1-14 * abstract * * page 2512, paragraph l - page 2515, column left, paragraph l *
 [X]  - NIRALA S K ET AL, "530 INTERCELLULAR COMMUNICATION THROUGH TUNNELING NANOTUBES: A POSSIBLE TARGET FOR ANTI-CANCER THERAPIES", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 50, doi:DOI:10.1016/S0168-8278(09)60532-8, ISSN 0168-8278, (20090401), page S197, (20090401), XP026496143 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1016/S0168-8278(09)60532-8
 [X]  - KASHIWADA Y ET AL, "ANTITUMOR AGENTS, 129. TANNINS AND RELATED COMPOUNDS AS SELECTIVE CYTOTOXIC AGENTS", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, (19920801), vol. 55, no. 8, doi:DOI:10.1021/NP50086A002, ISSN 0163-3864, pages 1033 - 1043, XP009064352 [X] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1021/np50086a002
 [X]  - OKUDA ET AL, "Systematics and health effects of chemically distinct tannins in medicinal plants", PHYTOCHEMISTRY, PERGAMON PRESS, GB, (20050901), vol. 66, no. 17, doi:DOI:10.1016/J.PHYTOCHEM.2005.04.023, ISSN 0031-9422, pages 2012 - 2031, XP005076919 [X] 1-13 * abstract * * "14.1. Inhibition of skin-tumor promotion by EGCG, pentagalloylglucose, ellagic acid and C-glucosidic ellagitannins""; page 2024 * * Paragraph linking pages 2025-2026 *

DOI:   http://dx.doi.org/10.1016/j.phytochem.2005.04.023
 [X]  - YOSHIMURA M ET AL, "Flavonol glucuronides and C-glucosidic ellagitannins from Melaleuca squarrosa", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 69, no. 18, doi:DOI:10.1016/J.PHYTOCHEM.2008.04.004, ISSN 0031-9422, (20081201), pages 3062 - 3069, (20080522), XP025744310 [X] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.phytochem.2008.04.004
 [X]  - ITO HIDEYUKI ET AL, "Anti-tumor promoting activity of polyphenols from Cowania mexicana and Coleogyne ramosissima", CANCER LETTERS, NEW YORK, NY, US, vol. 143, no. 1, doi:DOI:10.1016/S0304-3835(99)00160-3, ISSN 0304-3835, (19990823), pages 5 - 13, (19990723), XP009147210 [X] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0304-3835(99)00160-3
 [X]  - MARZOUK MOHAMED S A ET AL, "Anticancer and antioxidant Tannins from Pimenta dioica leaves", ZEITSCHRIFT FUER NATURFORSCHUNG. C, A JOURNAL OF BIOSCIENCES, TUEBINGEN, DE, (20070701), vol. 62, no. 7-8, ISSN 0939-5075, pages 526 - 536, XP009147300 [X] 1-13 * abstract *
 [XD]  - HOFFMANN O ET AL, "Potent inhibitory effect of naturally occurring ellagitannins on in vitro osteoclastic bone resorption", BONE, PERGAMON PRESS., OXFORD, GB, (20061101), vol. 39, no. 5, ISSN 8756-3282, pages S9 - S10, XP009147298 [XD] 1-14 * abstract *
 [X]  - TAGURI TOSHITSUGU ET AL, "Antimicrobial activity of 10 different plant polyphenols against bacteria causing food-borne disease.", BIOLOGICAL & PHARMACEUTICAL BULLETIN DEC 2004 LNKD- PUBMED:15577214, (200412), vol. 27, no. 12, ISSN 0918-6158, pages 1965 - 1969, XP002633776 [X] 1-13 * abstract * * table 3 * * Paragraph linking left and right columns on page 1969 *
 [X]  - ITO H, "Oxidized ellagitannins in medicinal plants and their biological activities", NATURAL MEDICINES - SHOYAKUGAKU ZASSHI, JAPANESE SOCIETY OF PHARMACOGNOSY, TOKYO, JP, (20050401), vol. 59, no. 2, ISSN 1340-3443, pages 57 - 62, XP009147315 [X] 1-13 * the whole document *
by applicant   - CHEM PHARM BULL., (1995), vol. 43, no. 11, pages 2033 - 5
    - BIOCHEM BIOPHYS RES COMMUN., (2004), vol. 325, no. 4, pages 1472 - 80
    - BONE, (2006), vol. 39, no. 5, pages 3 - 40
    - QUIDEAU ET AL., CHEM. EUR. J., (2005), vol. 11, pages 6503 - 6513
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.